Novo Nordisk: no intention to bid for Ablynx again
(CercleFinance.com) - Denmark's Novo Nordisk does not intend to make another offer for Ablynx, the firm said on Monday after the Belgian biopharmaceutical company accepted a 3.
9 billion euro bid from Sanofi.
"Novo Nordisk today confirms that it will not be making a revised proposal," the Danish drugmaker said on Monday, while expressing its intention to continue its research collaboration with Ablynx.
As a reminder, on 8 January Ablynx rejected a 2.6 billion euros bid approach from the Danish diabetes heavyweight, saying it undervalued the company and its "enormous upside."
Copyright (c) 2018 CercleFinance.com. All rights reserved.
9 billion euro bid from Sanofi.
"Novo Nordisk today confirms that it will not be making a revised proposal," the Danish drugmaker said on Monday, while expressing its intention to continue its research collaboration with Ablynx.
As a reminder, on 8 January Ablynx rejected a 2.6 billion euros bid approach from the Danish diabetes heavyweight, saying it undervalued the company and its "enormous upside."
Copyright (c) 2018 CercleFinance.com. All rights reserved.